Jeffrey Davidson

1 Introduction Diabetic foot ulcers (DFUs) are associated with high rates of lower limb amputation and increased patient mortality [1]. The DFU microenvironment is complex—involving persistent inflammation, dysregulation of fibroblasts and keratinocytes, imbalanced extracellular matrix (ECM) production, oxidative stress, and metabolic dysfunction, all of which delay wound healing [2]. With an aging population and rising diabetes rates, there is a pressing need to improve DFU therapies.